In sickle cell disease, hydroxyurea plays a crucial role by inducing the production of fetal hemoglobin (HbF). The increased levels of HbF help to reduce the sickling of red blood cells, thereby alleviating symptoms and complications associated with the disease. While this does not directly correct the genetic mutation causing SCD (a single nucleotide mutation in the HBB gene), it provides symptomatic relief and reduces severe episodes of pain.
